Wall Street Rebounds Amid Oil Price Volatility
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 15 hours ago
0mins
Should l Buy SLS?
Source: stocktwits
- Semiconductor Stocks Lead Gains: Semiconductor stocks such as Broadcom, Micron, AMD, and Nvidia posted strong gains during Wall Street's rebound, indicating a recovery in investor confidence towards tech stocks amid volatile market conditions.
- Oil Price Volatility: Oil prices experienced dramatic swings, with West Texas Intermediate crude briefly surging to $119 per barrel after President Trump suggested the Iran conflict might be nearing an end, before retreating to the low $80s, highlighting the significant impact of geopolitical events on oil markets.
- Shifts in Market Sentiment: Despite major indexes rebounding sharply in the previous session, Nasdaq 100 and S&P 500 futures traded down about 0.4% late Monday, reflecting investor caution ahead of key economic data and earnings reports.
- Investor Focus on Upcoming Data: The market is closely watching the NFIB Small Business Optimism Index and existing home sales data, while upcoming earnings reports from Oracle and Adobe are expected to serve as important catalysts for market movement.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy SLS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on SLS
Wall Street analysts forecast SLS stock price to rise
2 Analyst Rating
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 5.960
Low
7.00
Averages
7.25
High
7.50
Current: 5.960
Low
7.00
Averages
7.25
High
7.50
About SLS
SELLAS Life Sciences Group, Inc. is a late-stage clinical biopharmaceutical company. The Company is focused on the development of therapeutics for a range of cancer indications. The Company's product candidates are galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1 (WT1), antigen, and SLS009, a selective small molecule cyclin-dependent kinase 9 (CDK9) inhibitor. GPS is a cancer immunotherapeutic agent licensed by Memorial Sloan Kettering Cancer Center (MSK), that targets the WT1 protein, which is present in an array of tumor types. GPS has potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic malignancies and solid tumor indications. The Company is developing SLS009, which is licensed by GenFleet Therapeutics (Shanghai), Inc., for all therapeutic and diagnostic uses in the world outside of mainland China, Hong Kong, Macau, and Taiwan.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Sellas Immunotherapy Advances with Galinpepimut-S
- Immunotherapy Innovation: Sellas' lead immunotherapy Galinpepimut-S (GPS) targets the Wilms Tumor-1 (WT1) antigen, activating multiple T cells to effectively attack leukemic stem cells and residual cancer cells, indicating broad applicability of the treatment.
- Clinical Trial Progress: The investor-focused Phase 3 Regal trial is nearing final analysis, with 72 survival events recorded, just shy of the 80-event threshold needed to assess overall survival impact, suggesting potential positive outcomes.
- Market Reaction: Despite a 1.5% drop in premarket trading on Monday, Sellas Life Sciences' stock surged nearly 5% on Friday to $5.53, reflecting strong market interest and investor confidence in its immunotherapy developments.
- Investor Sentiment: On Stocktwits, retail sentiment for SLS was 'bullish' with a 68% increase in message volume over 24 hours, indicating optimism among investors regarding the Regal trial and SLS009 drug, viewed as a lifeline for patients and a hopeful prospect for investors.
See More
Sellas' Immunotherapy Trial Approaches Key Milestone
- Clinical Trial Progress: Sellas' Phase 3 Regal trial is testing the immunotherapy Galinpepimut-S (GPS) as a maintenance treatment for acute myeloid leukemia (AML) patients, with only eight more events needed to trigger the final analysis, indicating significant progress in the clinical study.
- Stock Price Surge: Shares of Sellas Life Sciences Group Inc. (SLS) rallied nearly 8% on Monday to close at $5.96, reaching a four-year high, reflecting investor optimism ahead of the anticipated clinical data release, despite some analysts expressing bearish views on the drug's efficacy.
- Investor Sentiment Shift: Over the past 24 hours, SLS saw a 580% surge in message volume on Stocktwits, with sentiment shifting from 'bullish' to 'extremely bullish', highlighting the market's heightened focus on the upcoming trial results.
- CEO Endorses Strategy: Sellas CEO Angelos Stergiou stated that GPS will target leukemia regardless of genetic mutations, aiming to activate multiple types of T cells to attack leukemic stem cells, further bolstering market confidence in the therapy.
See More
Wall Street Rebounds Amid Oil Price Volatility
- Semiconductor Stocks Lead Gains: Semiconductor stocks such as Broadcom, Micron, AMD, and Nvidia posted strong gains during Wall Street's rebound, indicating a recovery in investor confidence towards tech stocks amid volatile market conditions.
- Oil Price Volatility: Oil prices experienced dramatic swings, with West Texas Intermediate crude briefly surging to $119 per barrel after President Trump suggested the Iran conflict might be nearing an end, before retreating to the low $80s, highlighting the significant impact of geopolitical events on oil markets.
- Shifts in Market Sentiment: Despite major indexes rebounding sharply in the previous session, Nasdaq 100 and S&P 500 futures traded down about 0.4% late Monday, reflecting investor caution ahead of key economic data and earnings reports.
- Investor Focus on Upcoming Data: The market is closely watching the NFIB Small Business Optimism Index and existing home sales data, while upcoming earnings reports from Oracle and Adobe are expected to serve as important catalysts for market movement.
See More
Sellas Life Sciences Stock Volatility Amid AML Summit Insights
- Clinical Trial Progress: Sellas' Phase 3 Regal trial for acute myeloid leukemia (AML) has recorded 72 survival events, just 8 short of the 80 needed to trigger the final analysis, indicating that the trial is nearing a critical juncture that could significantly impact the company's future market performance.
- Investor Focus on Summit: Investors are closely monitoring the Miami Cancer Institute Immunotherapies Summit, where Sellas' scientific advisor Guenther Koehne is set to deliver opening remarks, potentially providing crucial insights ahead of the upcoming Phase 3 trial readout, which could influence market sentiment.
- Stock Price Volatility: After a five-session winning streak, Sellas shares fell nearly 5% to $5.28 on Thursday, reflecting a cautious market attitude ahead of the clinical results, despite the stock having surged nearly 330% over the past year.
- Optimistic Market Sentiment: Despite the stock decline, retail sentiment on Stocktwits remains 'bullish', with many users expressing optimism about the GPS Phase 3 results, believing that the upcoming announcement will yield substantial returns for investors, indicating strong market confidence in Sellas' future prospects.
See More
Sellas Life Sciences Stock Soars Ahead of Key AML Trial Data
- Stock Price Surge: Sellas Life Sciences Group (SLS) shares have risen in 12 of the past 13 trading sessions, with a more than 4% increase on Wednesday to $5.54, reflecting strong investor anticipation surrounding its acute myeloid leukemia (AML) therapy.
- Rising Short Interest: Despite the stock's rally, short interest peaked at 29% in mid-January, indicating heightened investor focus on the upcoming Regal trial data, with short bets increasing by approximately 15% since December.
- Institutional Accumulation: Data from Quiver Quantitative reveals that about 40% of recent institutional activity involved new purchases, while roughly 75% of overall activity consisted of funds either buying or holding SLS shares, demonstrating institutional confidence in the stock.
- Acquisition Speculation: The sharp rally has intensified speculation among retail investors that SLS could become a takeover target for major pharmaceutical companies if the Regal trial succeeds, with retail sentiment remaining 'extremely bullish' over the past month.
See More
SELLAS Life Sciences Stock Surges Over 200% Amid Positive Trial Data
- Significant Stock Surge: SELLAS Life Sciences' stock has surged over 200% in the last six months, with a year-to-date increase of approximately 45%, indicating strong market performance that is attracting more investor interest.
- Short Squeeze Potential: With a short interest of 27.21% according to Benzinga Pro data, SELLAS could be a candidate for a short squeeze, potentially leading to further volatility in its stock price.
- Clinical Trial Progress: In December 2025, SELLAS presented clinical data showing that SLS009 in combination with AZA/VEN achieved a 46% overall response rate among 35 evaluable patients with relapsed AML, including a 29% complete response rate, demonstrating significant clinical activity.
- REGAL Trial Update: An update in December 2025 indicated that the REGAL trial is expected to reach the 80th event required for final analysis by year-end, reflecting the company's ongoing commitment to advancing treatments in the AML space.
See More
Sellas Immunotherapy Advances with Galinpepimut-S
- Immunotherapy Innovation: Sellas' lead immunotherapy Galinpepimut-S (GPS) targets the Wilms Tumor-1 (WT1) antigen, activating multiple T cells to effectively attack leukemic stem cells and residual cancer cells, indicating broad applicability of the treatment.
- Clinical Trial Progress: The investor-focused Phase 3 Regal trial is nearing final analysis, with 72 survival events recorded, just shy of the 80-event threshold needed to assess overall survival impact, suggesting potential positive outcomes.
- Market Reaction: Despite a 1.5% drop in premarket trading on Monday, Sellas Life Sciences' stock surged nearly 5% on Friday to $5.53, reflecting strong market interest and investor confidence in its immunotherapy developments.
- Investor Sentiment: On Stocktwits, retail sentiment for SLS was 'bullish' with a 68% increase in message volume over 24 hours, indicating optimism among investors regarding the Regal trial and SLS009 drug, viewed as a lifeline for patients and a hopeful prospect for investors.
See More
Sellas' Immunotherapy Trial Approaches Key Milestone
- Clinical Trial Progress: Sellas' Phase 3 Regal trial is testing the immunotherapy Galinpepimut-S (GPS) as a maintenance treatment for acute myeloid leukemia (AML) patients, with only eight more events needed to trigger the final analysis, indicating significant progress in the clinical study.
- Stock Price Surge: Shares of Sellas Life Sciences Group Inc. (SLS) rallied nearly 8% on Monday to close at $5.96, reaching a four-year high, reflecting investor optimism ahead of the anticipated clinical data release, despite some analysts expressing bearish views on the drug's efficacy.
- Investor Sentiment Shift: Over the past 24 hours, SLS saw a 580% surge in message volume on Stocktwits, with sentiment shifting from 'bullish' to 'extremely bullish', highlighting the market's heightened focus on the upcoming trial results.
- CEO Endorses Strategy: Sellas CEO Angelos Stergiou stated that GPS will target leukemia regardless of genetic mutations, aiming to activate multiple types of T cells to attack leukemic stem cells, further bolstering market confidence in the therapy.
See More
Wall Street Rebounds Amid Oil Price Volatility
- Semiconductor Stocks Lead Gains: Semiconductor stocks such as Broadcom, Micron, AMD, and Nvidia posted strong gains during Wall Street's rebound, indicating a recovery in investor confidence towards tech stocks amid volatile market conditions.
- Oil Price Volatility: Oil prices experienced dramatic swings, with West Texas Intermediate crude briefly surging to $119 per barrel after President Trump suggested the Iran conflict might be nearing an end, before retreating to the low $80s, highlighting the significant impact of geopolitical events on oil markets.
- Shifts in Market Sentiment: Despite major indexes rebounding sharply in the previous session, Nasdaq 100 and S&P 500 futures traded down about 0.4% late Monday, reflecting investor caution ahead of key economic data and earnings reports.
- Investor Focus on Upcoming Data: The market is closely watching the NFIB Small Business Optimism Index and existing home sales data, while upcoming earnings reports from Oracle and Adobe are expected to serve as important catalysts for market movement.
See More
Sellas Life Sciences Stock Volatility Amid AML Summit Insights
- Clinical Trial Progress: Sellas' Phase 3 Regal trial for acute myeloid leukemia (AML) has recorded 72 survival events, just 8 short of the 80 needed to trigger the final analysis, indicating that the trial is nearing a critical juncture that could significantly impact the company's future market performance.
- Investor Focus on Summit: Investors are closely monitoring the Miami Cancer Institute Immunotherapies Summit, where Sellas' scientific advisor Guenther Koehne is set to deliver opening remarks, potentially providing crucial insights ahead of the upcoming Phase 3 trial readout, which could influence market sentiment.
- Stock Price Volatility: After a five-session winning streak, Sellas shares fell nearly 5% to $5.28 on Thursday, reflecting a cautious market attitude ahead of the clinical results, despite the stock having surged nearly 330% over the past year.
- Optimistic Market Sentiment: Despite the stock decline, retail sentiment on Stocktwits remains 'bullish', with many users expressing optimism about the GPS Phase 3 results, believing that the upcoming announcement will yield substantial returns for investors, indicating strong market confidence in Sellas' future prospects.
See More
Sellas Life Sciences Stock Soars Ahead of Key AML Trial Data
- Stock Price Surge: Sellas Life Sciences Group (SLS) shares have risen in 12 of the past 13 trading sessions, with a more than 4% increase on Wednesday to $5.54, reflecting strong investor anticipation surrounding its acute myeloid leukemia (AML) therapy.
- Rising Short Interest: Despite the stock's rally, short interest peaked at 29% in mid-January, indicating heightened investor focus on the upcoming Regal trial data, with short bets increasing by approximately 15% since December.
- Institutional Accumulation: Data from Quiver Quantitative reveals that about 40% of recent institutional activity involved new purchases, while roughly 75% of overall activity consisted of funds either buying or holding SLS shares, demonstrating institutional confidence in the stock.
- Acquisition Speculation: The sharp rally has intensified speculation among retail investors that SLS could become a takeover target for major pharmaceutical companies if the Regal trial succeeds, with retail sentiment remaining 'extremely bullish' over the past month.
See More
SELLAS Life Sciences Stock Surges Over 200% Amid Positive Trial Data
- Significant Stock Surge: SELLAS Life Sciences' stock has surged over 200% in the last six months, with a year-to-date increase of approximately 45%, indicating strong market performance that is attracting more investor interest.
- Short Squeeze Potential: With a short interest of 27.21% according to Benzinga Pro data, SELLAS could be a candidate for a short squeeze, potentially leading to further volatility in its stock price.
- Clinical Trial Progress: In December 2025, SELLAS presented clinical data showing that SLS009 in combination with AZA/VEN achieved a 46% overall response rate among 35 evaluable patients with relapsed AML, including a 29% complete response rate, demonstrating significant clinical activity.
- REGAL Trial Update: An update in December 2025 indicated that the REGAL trial is expected to reach the 80th event required for final analysis by year-end, reflecting the company's ongoing commitment to advancing treatments in the AML space.
See More
